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117however, it might be related to vascular injuries that were more
frequent in patients with failed PCI, such as coronary perforation
(7.4% vs. 1.7%, p  0.01) and residual dissection (9.4% vs. 4.3%,
p  0.01), thereby exaggerating the relative benefits of a
successful opening of the occluded artery. Consistent with that,
our group previously reported analysis of a cohort of patients
with failed but uncomplicated CTO PCI procedures, showing
similar rates of death and myocardial infarction at a mean
follow-up of 2 years (2). It would be appropriate to repeat the
analysis of the authors and compare the successful PCI group
with the noncomplicated failed group and examine whether
their conclusion still holds.
Finally, with regard to the use of drug-eluting stents (DES)
versus bare-metal stents (BMS), the authors reported that treat-
ment with DES in comparison with BMS resulted in similar
definite/probable stent thrombosis rates (1.7% vs. 2.3%, p 0.58);
owever, only 4.2% of patients in the DES group versus 42% of the
atients in the BMS group reached 5-year follow-up. This major
ifference in follow-up time could lead to a bias as well.
We agree that performing a randomized clinical trial comparing
CI for CTO and conservative therapy with medications only,
uch as in the upcoming DECISION-CTO (Drug-Eluting Stent
mplantation vs. Optimal Medical Treatment in Patients with
hronic Total Occlusion) trial, might reveal whether treating
hese complex lesions has an effect on clinical result.
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Reply
We thank Dr. Movahed and Dr. Badr and colleagues for their
expressed interest in our study. Dr. Movahed refers to the potential
implications of the relatively high perforation rate observed in our
study (1). In our study, the definition we employed for coronary
perforation included any one of the 3 types proposed by Ellis et al.
(2). However, the specific type of perforation was not recorded. A
recent Bayesian meta-analysis by Shimony et al. (3) showed thatmorbidity and mortality after coronary perforation vary directly
with the Ellis classification. Mortality was 0.3%, 0.4%, and 21.2%
after type I, II, and III perforations, respectively, clearly indicating
that not every type of perforation is associated with catastrophic
outcomes.
In our study, 30-day mortality in patients with a coronary perfo-
ration was 0%, and 1-year mortality was 5.2%. Therefore, it is highly
unlikely that a significant number of type III perforations occurred.
Finally, the performance of coronary artery bypass surgery was not
within an urgent time frame, but within months of the failed
percutaneous coronary intervention (PCI) procedure, therefore re-
flecting the decision to proceed with complete revascularization at a
later point. Because of the low mortality rate after coronary perfora-
tion, we do not agree with the suggestion that chronic total occlusion
(CTO) PCI overall is associated with a poor outcome.
Nonetheless, we do acknowledge the fact that despite favorable
outcomes, the rate of this complication was high. Operators perform-
ing CTO intervention should make every effort to minimize this
potentially hazardous complication and should inform the patient of
the risk of a coronary perforation during the informed consent
process. Moreover, future randomized clinical trials investigating the
potential benefit of CTO PCI should carefully record the incidence,
types, and outcomes of coronary artery perforation.
Regarding the comments by Dr. Badr and colleagues, we agree that
our study is limited by its observational nature and by the fact that the
control group does not include patients assigned to medical therapy.
Nonetheless, as our control group consisted of patients with CTO
lesions that were deemed suitable for PCI, the applicability of the
study results extends beyond the mere intuitive fact that when a
procedure fails, it is bad for the patient. In the absence of randomized
controlled trials investigating the effect of PCI of CTOs compared
with medical therapy, we cannot exclude that part of the observed
worse outcome in the failed PCI group in our study may be attributed
to harmful effects of a failed procedure. The other part may be
attributed to a beneficial effect of a successful procedure.
Finally, we agree wholeheartedly that the results of well-designed
randomized controlled trials investigating a potential benefit of CTO
PCI, such as EXPLORE (Evaluating Xience V and Left Ventricular
Function in Percutaneous Coronary Intervention on Occlusions
after ST-Elevation Myocardial Infarction) (4), DECISION-CTO
(Drug-Eluting Stent Implantation vs. Optimal Medical Treat-
ment in Patients with Chronic Total Occlusion), and the EURO-
CTO (European Study on the Utilization of Revascularization vs.
Optimal Medical Therapy for the Treatment of Chronic Total
Coronary Occlusions) are eagerly awaited. Long-term follow-up of
these studies will also provide further insight into the safety and
efficacy of (newer-generation) drug-eluting stents in CTO lesions.
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